What's Happening?
Scholar Rock, a biopharmaceutical company, has resubmitted its Biologics License Application (BLA) for apitegromab to the U.S. Food and Drug Administration (FDA). Apitegromab is an investigational monoclonal antibody designed to treat spinal muscular
atrophy (SMA) by inhibiting myostatin activation in skeletal muscles. This resubmission follows a Complete Response Letter (CRL) from the FDA in September 2025, which was related to observations during a site inspection at Catalent Indiana, a facility involved in the drug's production. The CRL did not cite any specific concerns about apitegromab itself. Scholar Rock has since worked with the FDA and Catalent Indiana to address these issues, including adding a second U.S.-based fill-finish facility to strengthen the supply chain. The company anticipates FDA acceptance of the BLA within 30 days and a review period of up to six months, with a PDUFA action date expected in late September 2026.
Why It's Important?
The resubmission of the BLA for apitegromab is significant as it represents a potential advancement in the treatment of SMA, a rare and debilitating neuromuscular disease. Apitegromab is the first muscle-targeted therapy to show statistically significant improvements in motor function in clinical trials for SMA patients. If approved, it could provide a new therapeutic option for individuals with SMA, potentially improving their quality of life. The FDA's engagement and the drug's designations, such as Fast Track and Orphan Drug, highlight the urgency and importance of this treatment. Successful approval and commercialization could also bolster Scholar Rock's position in the biopharmaceutical industry, particularly in the field of neuromuscular diseases.
What's Next?
Scholar Rock expects the FDA to accept the BLA resubmission within 30 days, followed by a review period of up to six months. The company is preparing for potential approvals and launches of apitegromab in both the U.S. and Europe later this year. The European Medicines Agency (EMA) is also reviewing the Marketing Authorisation Application (MAA) for apitegromab, with a decision anticipated mid-2026. Scholar Rock plans to host a conference call to discuss these developments and provide further updates. The outcome of these regulatory reviews will be crucial for the company's future strategies and market presence.
